Enumeration and immunohistochemical characterisation of bone marrow basophils in myeloproliferative disorders using the basophil specific monoclonal antibody 2D7

Journal of Clinical Pathology

Volumn 59, Issue 4, 2006, Pages 396-402

  Agis, H ^a   Krauth, M T ^a   Mosberger, I ^a   Mullauer L ^a   Simonitsch Klupp, I ^a   Schwartz, L B ^b   Printz, D ^c   Bohm A ^a   Fritsch, G ^c   Horny, H P ^d   Valent, Peter ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ST ANNA CHILDREN S HOSPITAL   (Austria)

^d UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD9 ANTIGEN; HISTIDINE DECARBOXYLASE; LEUKOSIALIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2D7; MYELOPEROXIDASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; BASOPHIL; BLOOD CELL COUNT; BONE MARROW CELL; CHRONIC MYELOID LEUKEMIA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; POLYCYTHEMIA VERA; PRIORITY JOURNAL; SYSTEMIC MASTOCYTOSIS; T LYMPHOCYTE; THROMBOCYTHEMIA;

ADULT; AGED; ANTIBODIES, MONOCLONAL; BASOPHILS; BIOLOGICAL MARKERS; BONE MARROW CELLS; FEMALE; HISTAMINE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LEUKEMIA, MYELOID, CHRONIC; LEUKOCYTE COUNT; MALE; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS;

EID: 33645715502     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2005.029215     Document Type: Article

References (47)

1. Valent P, Bettelheim P. The human basophil. Crit Rev Oncol Hematol 1990;10:327-52.
2. Dvorak AM. Cell biology of the basophil. Int Rev Cytol 1998;180:87-236.
3. Falcone FH, Haas H, Gibbs BF. The human basophil: a new appreciation of its role in immune responses. Blood 2000;96:4028-38.
4. Schroeder JT, MacGlashan DW, Lichtenstein LM. Human basophils: mediator release and cytokine production. Adv Immunol 2001;77:93-122.
5. Dvorak AM. Histamine content and secretion in basophils and mast cells. Prog Histochem Cytochem 1998;33:169-320.
6. Denburg JA, Davison M, Bienenstock J. Basophil production. J Clin Invest 1980;65:390-9.
7. Leary AG, Ogawa M. Identification of pure and mixed basophil colonies in culture of human peripheral blood and marrow cells. Blood 1984;64:78-83.
8. Saito H, Hatake K, Dvorak AM, et al. Selective differentiation and proliferation of hematopoietic cells induced by recombinant human interleukins. Proc Natl Acad Sci USA 1988;85:2288-92.
9. Valent P, Schmidt G, Besemer J, et al. Interleukin-3 is a differentiation factor for human basophils. Blood 1989;73:1763-9.
10. Stain C, Stockinger H, Scharf M, et al. Human blood basophils display a unique phenotype including activation linked membrane structures. Blood 1998;70:1872-9.
11. Bodger MP, Newton LA. The purification of human basophils: their immunophenotype and cytochemistry. Br J Haematol 1987;67:281-4.
12. MacGlashan DW, Schleimer RP, Peters SP, et al. Comparative studies of human basophils and mast cells. Fed Proc 1983;42:2504-9.
13. de Boer M, Roos D. Metabolic comparison between basophils and other leukocytes from human blood. J Immunol 1986;136:3447-54.
14. Valent P, Majdic O, Maurer D, et al. Further characterization of surface membrane structures expressed on human basophils and mast cells. Int Arch Allergy Appl Immunol 1990;91:198-203.
15. Valent P, Bettelheim P. Cell surface structures on human basophils and mast cells: biochemical and functional characterization. Adv Immunol 1992;52:333-423.
16. Agis H, Füreder W, Bankl HC, et al. Comparative immunophenotypic analysis of human mast cells, blood basophils and monocytes. Immunology 1996;87:535-43.
17. Agis H, Beil WJ, Bankl HC, et al. Mast cell-lineage versus basophil lineage involvement in myeloproliferative and myelodysplastic syndromes: diagnostic role of cell-immunophenotyping. Leuk Lymphoma 1996;22:187-204.
18. Bühring HJ, Simmons PJ, Pudney M, et al. The monoclonal antibody 97A6 defines a novel surface antigen expressed on human basophils and their multipotent and unipotent progenitors. Blood 1999;94:2343-56.
19. Juhlin L. Basophil and eosinophil leukocytes in various internal disorders. Acta Med Scand 1963;174:249-54.
20. Spiers AS, Bain BJ, Turner JE. The peripheral blood in chronic granulocytic leukaemia. Study of 50 untreated Philadelphia-positive cases. Scand J Haematol 1977;18:25-38.
21. Gilbert HS. Myelofibrosis revisited: characterization and classification of myelofibrosis in the setting of myeloproliferative disease. Prog Clin Biol Res 1984;154:3-17.
22. Arnalich F, Lahoz C, Larrocha C, et al. Incidence and clinical significance of peripheral and bone marrow basophilia. J Med 1987;18:293-303.
23. Gomez GA, Sokal JE, Walsh D. Prognostic features at diagnosis of chronic myelocytic leukemia. Cancer 1981;47:2470-7.
24. Denburg JA, Wilson WE, Bienenstock J. Basophil production in myeloproliferative disorders: increases during acute blastic transformation of chronic myeloid leukemia. Blood 1982;60:113-20.
25. Mühleck SD, McKenna RW, Arthur DC, et al. Transformation of chronic myelogenous leukemia: clinical, morphologic, and cytogenetic features. Am J Clin Pathol 1984;82:1-14.
26. Kantarjian HM, Dixon D, Keating MJ, et al. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer 1988;61:1441-6.
27. Braga GW, Chauffaille ML, Moncau JE, et al. Chronic myeloid leukemia (CML): prognostic factors and survival analysis. Rev Paul Med 1996;114:1083-90.
28. Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998;90:850-8.
29. Steegmann JL, Odriozola J, Rodriguez-Salvanes F, et al. Stage, percentage of basophils at diagnosis, hematologic response within six months, cytogenetic response in the first year: the main prognostic variables affecting outcome in patients with chronic myeloid leukemia in chronic phase treated with interferon-alpha. Results of the CML89 trial of the Spanish Collaborative Group on interferon-alpha2a and CML. Haematologica 1999;84:978-87.
30. Bosma TJ, Kennedy MA, Bodger MP, et al. Basophils exhibit rearrangement of the bcr gene in Philadelphia chromosome-positive chronic myeloid leukemia. Leukemia 1998;2:141-3.
31. Bodger MP, Morris CM, Kennedy MA, et al. Basophils (Bsp-1+) derive from the leukemic clone in human myeloid leukemias involving the chromosome breakpoint 9q34. Blood 1989;73:777-81.
32. McEuen AR, Buckley MG, Compton SJ, et al. Development and characterization of a monoclonal antibody specific for human basophils and the identification of a unique secretory product of basophil activation. Lab Invest 1999;79:27-38.
33. Kepley CL, Craig SS, Schwartz LB: Identification and partial characterization of a unique marker for human basophils. J Immunol 1995;154:6548-55.
34. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292-302.
35. Jaffe ES, Harris NL, Stein H, et al. In: WHO classification of tumours, Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press, 2001.
36. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981;29:577-80.
37. Cattoretti G, Pileri S, Parravicini C, et al. Antigen unmasking on formalin-fixed, paraffin-embedded tissue sections. J Pathol 1993;171:83-98.
38. Horny HP, Sillaber C, Menke D, et al. Diagnostic value of immunostaining for tryptase in patients with mastocytosis. Am J Surg Pathol 1998;22:1132-40.
39. Jordan JH, Walchshofer S, Jurecka W, et al. Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: evidence for expression of CD2, CD117/Kit, and bcl-x(L). Hum Pathol 2001;32:545-52.
40. Schernthaner GH, Jordan JH, Ghannadan M, et al. Expression, epitope analysis, and functional role of the LFA-2 antigen detectable on neoplastic mast cells. Blood 2001;98:3784-92.
41. Irani AM, Huang C, Xia HZ, et al. Immunohistochemical detection of human basophils in late-phase skin reactions. J Allergy Clin Immunol 1998;101:354-62.
42. Nouri-Aria KI, Irani AM, Jacobson MR, et al. Basophil recruitment and IL-4 production during human allergen-induced late asthma. J Allergy Clin Immunol 2001;108:205-11.
43. Wilson DR, Irani AM, Walker SM, et al. Grass pollen immunotherapy inhibits seasonal increases in basophils and eosinophils in the nasal epithelium. Clin Exp Allergy 2001;31:1705-13.
44. Füreder W, Agis H, Sperr WR, et al. The surface membrane antigen phenotype of human blood basophils. Allergy 1994;49:861-5.
45. Vardiman JD, Pierre R, Thiele J, et al. Chronic myelogenous leukaemia. In: WHO classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press, 2001:20-26.
46. Li Y, Li L, Wadley R, et al. Mast cells/basophils in the peripheral blood of allergic individuals who are HIV-1 susceptible due to their surface expression of CD4 and the chemokine receptors CCR3, CCR5, and CXCR4. Blood 2001;97:3484-90.
47. Foster B, Schwartz LB, Devouassoux G, et al. Characterization of mast-cell tryptase-expressing peripheral blood cells as basophils. J Allergy Clin Immunol 2002;109:287-93.